Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized single-blind study of BAY 1007626 intrauterine system versus Mirena and Jaydess
NL-OMON42633Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Jul 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bay-1007626, avatrombopag and LoviOne in contraception (3 arms), sponsored by Bayer. Primary endpoints: Number of bleeding and spotting days, Endometrial histology and 1 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
bay-1007626avatrombopagLoviOne
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON42633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42633.